India, April 15 -- French drugmajor Sanofi (SNY) announced Tuesday new progress from its mid- to late-stage respiratory pipeline, including preliminary phase 2 results for amlitelimab in adults with moderate-to-severe asthma.
In its statement, Sanofi announced that preliminary results from the TIDE-Asthma phase 2 study show that the primary endpoint of annualized exacerbation rate at week 48 was not met at the highest dose level, leading to nominal significance at the medium and low doses.
However, the study demonstrated amlitelimab's compelling efficacy in heterogeneous inflammatory asthma, potentially representing a breakthrough for this underserved patient population if observed in later studies.
Further, Lunsekimig is now targeting c...